The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease

Roseanne De Fronzo Dobkin; Matthew Menza; Karina L. Bienfait; Michael Gara; Humberto Marin; Margery H. Mark; Allison Dicke; Alexander Tröster

doi:10.1176/jnp.2010.22.2.188

The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease

Roseanne De Fronzo Dobkin, Matthew Menza, Karina L. Bienfait, Michael Gara, Humberto Marin, Margery H. Mark, Allison Dicke, Alexander Tröster

Research output: Contribution to journal › Article › peer-review

31 Scopus citations

Abstract

Depression is associated with more rapid cognitive decline in Parkinson's disease. The goal of this study was to examine the impact of the acute (8-week) and longer-term (24-week) antidepressant treatment on cognition in Parkinson's disease and to detail cognitive predictors of treatment response. Fifty-two depressed Parkinson's disease patients were enrolled in an NIH-funded randomized, controlled trial of nortriptyline, paroxetine, and placebo. Neuropsychological testing was performed at baseline and weeks 8 and 24. Higher baseline scores on measures of executive functioning, speed of processing, and verbal memory were associated with antidepressant response. Treatment responders did not exhibit larger gains in cognition than nonresponders. Findings warrant replication.

Original language	English (US)
Pages (from-to)	188-195
Number of pages	8
Journal	Journal of Neuropsychiatry and Clinical Neurosciences
Volume	22
Issue number	2
DOIs	https://doi.org/10.1176/jnp.2010.22.2.188
State	Published - 2010

All Science Journal Classification (ASJC) codes

Clinical Neurology
Psychiatry and Mental health

Access to Document

10.1176/jnp.2010.22.2.188

Cite this

@article{1f3b191f5574471a960a1b8bda34eed2,

title = "The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease",

abstract = "Depression is associated with more rapid cognitive decline in Parkinson's disease. The goal of this study was to examine the impact of the acute (8-week) and longer-term (24-week) antidepressant treatment on cognition in Parkinson's disease and to detail cognitive predictors of treatment response. Fifty-two depressed Parkinson's disease patients were enrolled in an NIH-funded randomized, controlled trial of nortriptyline, paroxetine, and placebo. Neuropsychological testing was performed at baseline and weeks 8 and 24. Higher baseline scores on measures of executive functioning, speed of processing, and verbal memory were associated with antidepressant response. Treatment responders did not exhibit larger gains in cognition than nonresponders. Findings warrant replication.",

author = "Dobkin, {Roseanne De Fronzo} and Matthew Menza and Bienfait, {Karina L.} and Michael Gara and Humberto Marin and Mark, {Margery H.} and Allison Dicke and Alexander Tr{\"o}ster",

year = "2010",

doi = "10.1176/jnp.2010.22.2.188",

language = "English (US)",

volume = "22",

pages = "188--195",

journal = "Journal of Neuropsychiatry and Clinical Neurosciences",

issn = "0895-0172",

publisher = "American Psychiatric Publishing Inc.",

number = "2",

}

TY - JOUR

T1 - The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease

AU - Dobkin, Roseanne De Fronzo

AU - Menza, Matthew

AU - Bienfait, Karina L.

AU - Gara, Michael

AU - Marin, Humberto

AU - Mark, Margery H.

AU - Dicke, Allison

AU - Tröster, Alexander

PY - 2010

Y1 - 2010

N2 - Depression is associated with more rapid cognitive decline in Parkinson's disease. The goal of this study was to examine the impact of the acute (8-week) and longer-term (24-week) antidepressant treatment on cognition in Parkinson's disease and to detail cognitive predictors of treatment response. Fifty-two depressed Parkinson's disease patients were enrolled in an NIH-funded randomized, controlled trial of nortriptyline, paroxetine, and placebo. Neuropsychological testing was performed at baseline and weeks 8 and 24. Higher baseline scores on measures of executive functioning, speed of processing, and verbal memory were associated with antidepressant response. Treatment responders did not exhibit larger gains in cognition than nonresponders. Findings warrant replication.

AB - Depression is associated with more rapid cognitive decline in Parkinson's disease. The goal of this study was to examine the impact of the acute (8-week) and longer-term (24-week) antidepressant treatment on cognition in Parkinson's disease and to detail cognitive predictors of treatment response. Fifty-two depressed Parkinson's disease patients were enrolled in an NIH-funded randomized, controlled trial of nortriptyline, paroxetine, and placebo. Neuropsychological testing was performed at baseline and weeks 8 and 24. Higher baseline scores on measures of executive functioning, speed of processing, and verbal memory were associated with antidepressant response. Treatment responders did not exhibit larger gains in cognition than nonresponders. Findings warrant replication.

UR - http://www.scopus.com/inward/record.url?scp=77952394139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952394139&partnerID=8YFLogxK

U2 - 10.1176/jnp.2010.22.2.188

DO - 10.1176/jnp.2010.22.2.188

M3 - Article

C2 - 20463113

AN - SCOPUS:77952394139

SN - 0895-0172

VL - 22

SP - 188

EP - 195

JO - Journal of Neuropsychiatry and Clinical Neurosciences

JF - Journal of Neuropsychiatry and Clinical Neurosciences

IS - 2

ER -

The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this